

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/581,990
Date Submitted: September 1, 2010		Filing Date	2/26/2007
(use as many sheets as necessary)		First Named Inventor	Himanshu BRAHMBHATT
		Art Unit	1632
		Examiner Name	Anoop Kumar SINGH
		Attorney Docket Number	060348-0145
Sheet	1	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁸
	F1	Letter from Knobbe Martens Olson & Bear LLP dated February 26, 2010.	
	F2	Manisha P. DESAI et al., "The Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells is Size Dependent", <i>Pharmaceutical Research</i> , Vol. 14, No. 11, 1997, pp. 1568-1573.	
	F3	Igor DMITRIYEV et al., "Ectodomain of Coxsackievirus and Adenovirus Receptor Genetically Fused to Epidermal Growth Factor Mediates Adenovirus Targeting to Epidermal Growth Factor Receptor-Positive Cells", <i>Journal of Virology</i> , Aug. 2000, Vol. 74, No. 15, pp. 6875-6884.	
	F4	Christoph MAMOT et al., "Epidermal Growth Factor Receptor (EGFR)-targeted Immunoliposomes Mediate Specific and Efficient Drug Delivery to EGFR- and EGFRVIII-overexpressing Tumor Cells", <i>Cancer Research</i> , June 2003, Vol. 63, 3154-3161.	
	F5	William F. SCHERER M.D. et al., "THE VIRAL RANGE IN VITRO OF A MALIGNANT HUMAN EPITHELIAL CELL (STRAIN HELA, GEY) - III. Studies with Pseudolymphocytic Choriomeningitis Virus General Discussion", <i>American Journal of Pathology</i> , Jan-Feb 31(1): 31-39 (1954).	
	F6	Masahisa WATARAI et al., "Interaction of Ipa Proteins of <i>Shigella flexneri</i> with $\alpha 5 \beta 1$ Integrin Promotes Entry of the Bacteria into Mammalian Cells", <i>J. Exp. Med.</i> Vol. 183, March 1999, pp. 991-999.	
	F7	Tibor PAL et al., "Plasmid-Associated Adherence of <i>Shigella flexneri</i> in a HeLa Cell Model", <i>INFECTION AND IMMUNITY</i> , Aug 1989, Vol. 57, No. 8, pp. 2580-2582.	
	F8	William F. SCHERER et al., "STUDIES OF THE PROPAGATION IN VITRO OF POLIOMYELITIS VIRUSES", <i>Journal of Experimental Medicine</i> , Vol. 97, No. 5, pp. 695-710 (1953).	
	F9	Aline JAFFE et al., "Minicell-Forming Mutants of <i>Escherichia coli</i> : Production of Minicells and Anucleate Rods", <i>Journal of Bacteriology</i> , Vol. 170, No. 7, July 1988, pp. 3094-3101.	
	F10	Thomas L. HALE et al., "Characterization of Virulence Plasmids and Plasmid-Associated Outer Membrane Proteins in <i>Shigella flexneri</i> , <i>Shigella sonnei</i> , and <i>Escherichia coli</i> ", <i>Infection and Immunity</i> , April 1983, Vol. 40, No. 1, pp. 340-350.	
	F11	Gary J. DOHERTY et al., "Mechanisms and Endocytosis", <i>Annu. Rev. Biochem.</i> March 14, 2009, 78:311-3146.	
	F12	Pascal PESCHARD, "Escape from Cbl-mediated downregulation: A recurrent theme for oncogenic deregulation of receptor tyrosine kinases", <i>CANCER CELL</i> , June 2003, Vol. 3, pp. 519-523.	
	F13	Emmanouil D. KARAGIANNIS et al., "Minicells overcome tumor drug-resistance", <i>NATURE BIOTECHNOLOGY</i> , Vol. 27, No. 7, July 2009, pp. 620-621.	

Examiner Signature	/Anoop Singh/	Date Considered	09/07/2011
---------------------------	---------------	------------------------	------------

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

WASH_7297262.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.S./

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: September 1, 2010 <i>(use as many sheets as necessary)</i>				Complete if Known <table border="1"> <tr> <td>Application Number</td> <td>10/581,990</td> </tr> <tr> <td>Filing Date</td> <td>2/26/2007</td> </tr> <tr> <td>First Named Inventor</td> <td>Himanshu BRAHMBHATT</td> </tr> <tr> <td>Art Unit</td> <td>1632</td> </tr> <tr> <td>Examiner Name</td> <td>Anoop Kumar SINGH</td> </tr> <tr> <td>Attorney Docket Number</td> <td>060348-0145</td> </tr> </table>				Application Number	10/581,990	Filing Date	2/26/2007	First Named Inventor	Himanshu BRAHMBHATT	Art Unit	1632	Examiner Name	Anoop Kumar SINGH	Attorney Docket Number	060348-0145
Application Number	10/581,990																		
Filing Date	2/26/2007																		
First Named Inventor	Himanshu BRAHMBHATT																		
Art Unit	1632																		
Examiner Name	Anoop Kumar SINGH																		
Attorney Docket Number	060348-0145																		
Sheet	2	of	2																

[illegible]

Examiner Signature	/Anoop Singh/	Date Considered	09/07/2011
-----------------------	---------------	--------------------	------------

***EXAMINER.** Initial if reference considered; whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov/patent/basics/kinds.htm. 3 Is there a Senior Citizen? If yes, attach Senior Citizen fee. 4 Chief Officer that issued the document, by the two-letter code (WIPO) Standard ST 16. 5 For Japanese patent documents, indicate the date of publication under the reign of the Emperor of Japan according to the Imperial Household Agency website (<http://www.kokoro.go.jp>). Symbols as indicated on the document under WIPO Standard ST 16. 6 Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.58. The information is required to obtain or retain a benefit by the public which is to file (and/or publish) the invention in another country without loss of right of priority. It may also be used by others who wish to claim priority from your application. After gathering, preparing, and submitting the completed application forms to the USPTO Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer: U.S. Patent and Trademark Office, Washington D.C., 20590-6000. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1589, Arlington VA 22203-1589

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.